Digestive Care Consultants in Torrance, California: Physicians and gastroenterologists providing gastrointestinal endoscopy and colonoscopy; diagnosis and treatment of irritable bowel syndrome (IBS), Crohns disease, GERD, Holt, colon cancer, dyspepsia and achalasia.Colon, Pancreas, Stomach, Gall Bladder, Small Intestine, Liver: examination, diagnosis and treatment

23451 Madison St. #290 
Torrance, CA 90505 
(310) 375-1246 
fax (310) 375-0590 

James A. Sattler, M.D.


 

Education

1982-1984     Gastroenterology / Hepatology Fellow: Kaiser Foundation Hospital - Los Angeles, California
1980-1982     Residency: Kaiser Foundation Hospital - Los Angeles, California
1979-1980     Internship: Kaiser Foundation Hospital - Los Angeles, California
1978-1979     Doctor of Medicine: University of Southern California
1975-1978     Bachelor of Arts - Psychology, University of California, Berkeley




Honors

      Phi Beta Kappa, Alpha Omega Alpha
1988     Internist of the Year
Southern California Permanente Medical Group
Los Angeles Medical Center


Certifications

American Board of Internal Medicine, 1982
American Board of Internal Medicine, Gastroenterology Subspecialty, 1985


Hospital Affiliations

1999-Present     HealthSouth, Surgery Center of South Bay
Torrance, California
1990-Present     Active Affiliation, Little Company of Mary
Torrance, California
1990-Present     Active Affiliation, Torrance Memorial Medical Center
Torrance, California
1990-Present     Active Affiliation, San Pedro Hospital
San Pedro, California


Professional Affiliations

Member, American College of Physicians
Member, Southern California Society of Gastrointestinal Endoscopy
Associate Member, American Gastroenterology


Work Experience

2002-Present     Medical Director - Endoscopy Center at Skypark, Torrance, CA
1999-Present     Western Clinical Research, Inc., Torrance, CA
1990-Present     Gastroenterologist Partner, Digestive Care Consultants
1986-1989     Assistant Director of the Adult Liver Transplantation Committee, Permanente Medical Group, Southern California Region, Los Angeles, California
1986-1989     Assistant Director, Internal Medicine - Kaiser Foundation Hospital, Los Angeles, California
1984-1989     Internist and Gastroenterologist - Kaiser Foundation Hospital, Los Angeles, California


Academic Appointments

1984-1989     Clinical Instructor of Medical Students, Interns - Kaiser Foundation Hospital, Los Angeles, California
1984-1989     Clinical Instructor of Gastroenterologist Fellows - Kaiser Foundation Hospital, Los Angeles, California


Research Activities

  1. A randomized, double-blind, placebo controlled, multicenter 2-week pilot study to evaluate the efficacy, safety and tolerability of XXX (25 and 100 mg bid) given orally in female patients with Irritable Bowel Syndrome with diarrhea (IBS-D)
  2. A 6-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, to Assess the Efficacy and Safety of XXXX (6mg BID) and Placebo in Female Patients with Dyspepsia
  3. A Multicenter, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Low-Dose XXXX in Male Patients with Irritable Bowel Syndrome
  4. Safety, Tolerance and Efficacy of Treatment with Subcutaneous XXX in Subjects With Steroid-Dependent Crohn's Disease
  5. A Randomized, Open-Label, Multicenter, Efficacy, Tolerability and Safety Study of XXX Vs. XXX in Interferon and Ribavirin Treatment Naïve Patients with Chronic Hepatitis C Infection
  6. A 24 Week Randomized, Open Label Study of Health Care Resource Use and Quality of Life and Productivity with XXX 1 mg. Twice Daily versus Traditional Therapy in Females With Non-Constipated Irritable Bowel Syndrome
  7. A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled Study of XXX In Females With Non-Constipated Irritable Bowel Syndrome
  8. Double-Blind, Placebo-Controlled Long-Term Extension Study to Evaluate the Nine Month Safety Profile of XXX in Non-Constipated IBS Patients
  9. Double-Blind, Placebo-Controlled, Randomized, Multicenter, Parallel-Group Dose-Ranging Study To Investigate The Efficacy And Safety Of XXX In Non-Constipated Patients With Irritable Bowel Syndrome
  10. A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Phase II Study to Assess The Clinical Efficacy of XXX in Male Subjects with Irritable Bowel Syndrome
  11. A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Trial Of XXX For Treatment Of Non-Ulcer Dyspepsia In Patients Without Helicobacter Pylori
  12. A Randomized, Double-Blind, Active Controlled, Parallel Group, Multicenter Study to Evaluate The Efficacy And Safety Of XXX and XXX In Patients With Active, Mild To Moderate Ulcerative Colitis
  13. Dose-Finding Safety And Efficacy Study Of XXX Treatment To Reduce The Occurrence Of Sporadic Adenomatous Colorectal Polyps AT One Year In Subjects With Intermediate Risk Of Developing Polyps And Colorectal Cancer
  14. Prevention Of Sporadic Colorectal Adenomas With XXX
  15. A Comparative Efficacy And Safety Study Of XXX Versus XXX (150 mg bid) For The Healing Of NSAID Associated Gastric Ulcers When Daily NSAID Use Is Continued
  16. A Comparative Efficacy And Safety Study Of XXX Versus Placebo For The Prevention Of Gastric Ulcers Associated With Daily NSAID use In Patients At Risk
  17. A Randomized, Double-Blind Trial Comparing The Early Profile Of Heartburn Relief Associated With XXX 20mg daily Versus XXX, 20mg Once Daily In Gastroesophageal Reflux Disease Patients With An Acute Or Documented History Of Erosive Esophagitis
  18. A Double-Blind, Placebo-Controlled Trial Of XXX Tablets, 20mg Once Daily In The Treatment Of Subjects Without Erosive Esophagitis And Have Symptoms Of Chronic Gastroesophageal Reflux Disease (GERD)
  19. A Phase III Study Of The Safety And Antiviral Activity Of XXX In Adults With Chronic Hepatitis B Infection Who Are Positive For Hepatitis B E Antigen
  20. A Preliminary Assessment Of Safety And Antiviral Activity Of Open-Label XXX Plus XXX Therapy In Subjects With Chronic Hepatitis B Who Have Viremia On Monotherapy In Other XXX Trials
  21. A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel Group, Multicenter, Study Of The Safety And Efficacy Of XXX In Subjects With Irritable Bowel Syndrome
  22. An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study To Evaluate Efficacy And Safety Of XXX In Subjects With Irritable Bowel Syndrome
  23. A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Phase II Study To Assess The Clinical Efficacy Of XXX In Male Subjects With Irritable Bowel Syndrome
  24. A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Study Of XXX In Female Subjects With Alternating (Diarrhea/Constipation) Irritable Bowel Syndrome
  25. A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study To Investigate The Safety And Efficacy Of 2mg TID Of XXX Over Twelve Weeks In Diarrhea-Predominant Irritable Bowel Syndrome Subjects
  26. A Randomized, Double-Blind Trial Comparing The Early Profile Of Heartburn Relief Associated With XXX, 20mg Daily Versus XXX 20mg Once Daily In Gastroesophageal Reflux Disease Patients With An Acute Or Documented History Of Erosive Esophagitis
  27. A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study, To Assess The Efficacy And Safety Of XXX (6mg. BID) And Placebo In Female Patients With Dyspepsia
  28. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Two-Week Pilot Study To Evaluate The Efficacy, Safety And Tolerability Of XXX (25 and 100mg. BID) Given Orally In Female Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
  29. A Multicenter, Double-Blind, Placebo-Controlled Efficacy And Safety Study Of Low-Dose XXX In Male Patients With Irritable Bowel Syndrome